Albert Bourla

Chairman and CEO at PFIZER

Board

Since January 2019

Age

63 years

Education

Holds a Doctor of Veterinary Medicine and a Ph.D. in Biotechnology of Reproduction.

Tenure

Joined Pfizer in 1993 and has held numerous leadership roles including President and General Manager of the Established Products Business Unit (2010-2013), Group President roles in February 2016 and June 2016, Chief Operating Officer from January 2018 to December 2018, before becoming Chief Executive Officer in January 2019 and Chairman in January 2020.

Also at PFIZER

Aamir Malik

Chief U.S. Commercial Officer and EVP

AdG

Alexandre de Germay

Chief International Commercial Officer and EVP

Chris Boshoff

Chief Scientific Officer and President, R&D

About

Albert Bourla was born in 1962 and has developed a passion for science and innovation from an early age. He pursued a career in veterinary medicine and biotechnology, earning advanced degrees that have laid the foundation for his success. His educational background provided him with the skills required to contribute significantly to the field of biopharmaceuticals.

Over the span of more than 25 years at Pfizer, he started his journey with the company in 1993 and steadily advanced through a variety of roles in key divisions. His career is highlighted by pivotal leadership positions, where he was responsible for strategic initiatives, product development, and driving global commercial operations. His contributions have been instrumental in the development of groundbreaking treatments, including playing a central role in the rapid development of the COVID-19 vaccine.

Beyond his roles within the company, he has been actively involved in shaping Pfizer’s corporate culture and strategy. His leadership has not only focused on scientific innovation and operational excellence but has also emphasized corporate social responsibility, diversity, and global healthcare equity. These initiatives under his stewardship have reinforced Pfizer's reputation as a leader in the biopharmaceutical industry.

$PFE Performance Under Albert Bourla

Past Roles

Organization	Role	Date Range	Details
Pfizer	Chief Operating Officer	January 2018 - December 2018	N/A
Pfizer	Group President, Pfizer Innovative Health	June 2016 - December 2017	N/A
Pfizer	Group President, Global Innovative Pharma Business	February 2016 - June 2016	Responsible for Vaccines, Oncology, and Consumer Healthcare since 2014
Pfizer	President and General Manager of Established Products Business Unit	December 2010 - December 2013	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount ($)	Payment Schedule	Additional Details
Base Salary	1,787,500	Annual	Fixed base salary for 2023
Aircraft Usage	154,520	Annual	Incremental cost for personal use of company aircraft
Financial Counseling	15,000	Annual	Allowance for financial counseling, including tax preparation and estate planning
Car Usage	23,733	Annual	Incremental cost for personal use of a car and driver
Security	789,495	Annual	Additional security protection due to heightened security risks
Other	2,443	Annual	Incidental items provided in connection with Pfizer business meetings
Savings Plan Contributions	16,500	Annual	Employer contributions under the Savings Plan
Supplemental Savings Plan Contributions	1,257,563	Annual	Employer contributions under the Supplemental Savings Plan

Performance Compensation

Data from FY 2023

Performance Share Awards (PSAs)

Metric [Unit/Scale]**	Value	Details
Grant Date	Feb 23, 2023	Date the PSAs were granted
Grant Date Fair Value	$8,745,187	Determined using the closing stock price on the grant date
Grant Date Stock Price	$42.30	Stock price on the grant date
Threshold Shares	0 shares	No payout if performance is below threshold
Target Shares	206,742 shares	Target award based on performance goals
Maximum Shares	413,484 shares	Cap on shares that can be earned if performance exceeds targets
Payout Range	0% to 200%	Determined by achievement of adjusted net income and total shareholder return (TSR) over 2023–2025
Vesting Schedule	3 years (extendable to 5 years)	PSAs vest on the third anniversary, with an option to extend vesting to the fifth anniversary if elected
Performance Period	2023–2025	Three-year period over which performance is measured

Total Shareholder Return Units (TSRUs)

Metric [Unit/Scale]**	Value	Details
Grant Date	Feb 23, 2023	Date the TSRUs were granted
Grant Date Fair Value	$8,761,683	TSRU award fair value on the grant date
Grant Date Stock Price	$42.30	Stock price on the grant date
Vesting Schedule	3 years	TSRUs vest on the third anniversary and are settled on the fifth or seventh anniversary

Non-Equity Incentive Plan Compensation

Metric [Unit/Scale]**	Value	Details
Threshold Payout	$0	Minimum payout threshold
Target Payout	$3,575,342	Target bonus payout if financial goals are met
Maximum Payout	$8,938,355	Maximum possible payout under the plan
Actual Payout	$0	No payout was made as Pfizer did not achieve the required financial targets in 2023
Performance Period	Jan 1, 2023 – Dec 31, 2023	Evaluation period for the non-equity incentive plan

Short-Term Incentive Bonus

Metric [Unit/Scale]**	Value	Details
Actual Bonus Award	$0	No short-term bonus awarded due to missed financial targets
Performance Period	2023	Financial performance period for short-term incentives

This comprehensive breakdown explains the performance compensation components for 2023, including detailed metrics, targets, vesting schedules, and performance periods with exact dollar amounts and share units as available.